key: cord-0687786-4ngmjtuu
authors: Ruaño, Gualberto; Ha, Toan
title: Living with respiratory viruses: The next saga in human/viral coexistence?
date: 2021-01-06
journal: Bioessays
DOI: 10.1002/bies.202000321
sha: 37bcca3133f6be50fae5572867c9c8e8df569048
doc_id: 687786
cord_uid: 4ngmjtuu

Testing for respiratory viruses and SARS‐CoV‐2 in clinical and epidemiological settings has contrasting purposes and utility. Symptomatic patients are best tested with respiratory virus panels to establish the pathogen and guide personalized treatment. Asymptomatic patients are tested for a single infectious pathogen to establish carrier status and guide containment. [Image: see text]

surveillance. These are very different scenarios in which to employ testing. The clinical scenario is safeguarded by the medical imperatives to diagnose and treat when the same symptoms could be caused by more than one virus, ideally disambiguating, and pinpointing the agent of respiratory illness. The outbreak of COVID-19 has placed the population scenario at the scale of screening in uncharted territory.

With the advent of multivirus testing panels in the population scenario, we will discover coinfection rates, and will likely identify carriers of the other viruses. How many individuals are coinfected? What do we advise them to do? There's no doubt that once we start testing for viruses, we will find them. Because of this plethora of potential positive test results, the medical profession usually applies great care in deciding what to test for: there must be a good clinical reason. But in the population screening mode, we will likely find numerous cases of individuals carrying various individual viruses and combinations. Viruses have been a companion of modern humans and Neanderthals since the dawn of the species, and we even carry some viruses integrated into our chromosomes.

Are we to insist on quarantine for individuals who test positive for all respiratory viruses? No. That would depend on the infectiousness of the virus, the severity of the illness it causes, and the availability of treatments. Beginning with the four previous coronaviruses, we can conclude that these are highly infectious but mild in severity. We have never routinely tested for them. In fact, these viruses were intermingled with adenovirus, rhinovirus, and respiratory syncytial virus as part of the common cold, and treated symptomatically. Influenza viruses are the most serious threats, as agents of the flu, but these have been managed with the annual preventative vaccine and treatments. With SARS-CoV-2, we are challenged with a virus that is very infectious and clinically menacing for vulnerable sectors of the population. But an asymptomatic positive individual is a far less serious situation than a positive symptomatic patient. We will discover that a substantial portion of the population is asymptomatic and positive for some of these respiratory viruses, but that ultimately it is the clinical symptoms and vulnerability that drive care.

There is now a documented mutation conferring higher infectiousness in SARS-CoV-2, to the point where the variant constitutes more than 95% of infectious cases in the United States, Europe, and Asia.

There is also a concurrent decline in virulence, which could be a result of native immunity in the large population of asymptomatic patients. In fact, the common coronaviruses are also transmitted via zoonoses, which could have been virulent, but "morphed" into the common cold over time. SARS-CoV-2 may end joining its relatives 229E, HKU1, NL63, and OC43 as the fifth common coronavirus (Orent, 2020; assessed November 15, 2020). An estimated R0 of 2.5 (ranging from

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

WHO declares COVID-19 a pandemic

Human coronavirus-229E, -OC43, -NL63, and -HKU1. Reference module in life sciences

Biosensors for the detection of respiratory viruses: A review

Characteristics of SARS-CoV-2 and COVID-19